Clinical Trial Update: Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluating the combination of romidepsin and oral azacitidine in relapsed/refractory lymphoid malignancies, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Istodax (romidepsin)
• Onureg (azacitidine)

Snippet

Sponsor: Columbia University | Conditions: Lymphoid Malignancies, Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-22